as 12-20-2024 4:00pm EST
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
Founded: | 2014 | Country: | Italy |
Employees: | N/A | City: | N/A |
Market Cap: | 96.0M | IPO Year: | 2021 |
Target Price: | $25.00 | AVG Volume (30 days): | 5.8K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.52 | EPS Growth: | N/A |
52 Week Low/High: | $2.20 - $7.28 | Next Earning Date: | 01-01-0001 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
GNTA Breaking Stock News: Dive into GNTA Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
GlobeNewswire
2 months ago
Simply Wall St.
2 months ago
MT Newswires
3 months ago
GlobeNewswire
3 months ago
Insider Monkey
3 months ago
GOBankingRates
6 months ago
GOBankingRates
6 months ago
The information presented on this page, "GNTA Genenta Science S.p.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.